Episode 62
Biotech Hangout
00:00
ASCO's Immunogen Survival Data
There's a lot of news from ASCO and just generally in oncology, let's start with the immunogen survival data. It looks like you got like four months of survival benefit and two months of PFS benefit for elikir. Could there be an aspect of pseudo progression at play? I don't think they really address that question. But it probably doesn't matter because the data is the data.
Transcript
Play full episode
